Form 4: Lilly Endowment Inc. Sells $156 Million Worth of Eli Lilly & Co. Shares

Lilly Endowment Inc., a major shareholder of Eli Lilly & Co., has sold a significant portion of its holdings in multiple transactions on February 25, 2025.

Summary

• Lilly Endowment Inc. sold 171,450 shares of Eli Lilly & Co. (LLY) on February 25, 2025.
• The sales were executed in multiple transactions at weighted average prices ranging from $900.501 to $911.549 per share.
• The total value of shares sold is approximately $155.6 million.
• Following these transactions, Lilly Endowment Inc. still holds a substantial 96,236,978 shares of Eli Lilly & Co.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine transaction disclosure. The sale itself doesn't necessarily indicate a negative outlook, but it doesn't provide a positive signal either.

Risks

• Large sales by major shareholders can sometimes create short-term price volatility in the stock.

Industry Context

Sales by major shareholders are a common occurrence and are often related to portfolio rebalancing or philanthropic activities. The impact on the stock price depends on the size of the sale relative to the trading volume and overall market sentiment.

Comparison to Industry Standards

• Block trades of this size are not uncommon among large institutional holders.
• Comparable transactions would include similar sales by major shareholders in other large-cap pharmaceutical companies such as Johnson & Johnson (JNJ) or Pfizer (PFE).

Stakeholder Impact

• The sale could potentially cause a minor, temporary dip in the stock price, affecting shareholders in the short term.
• However, given the large number of shares still held by Lilly Endowment Inc., their long-term commitment to the company appears to remain strong.

Key Dates